Sideline Gold on Fe...
Health Care: Drugs
Teva Pharmaceutical Industries Ltd (TEVA: NYSE)
$39.64 0.32 | 0.81%
06/18/13 - 04:03 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 39.64 |
| 52 Week High | 42.83 |
| 52 Week Low | 36.63 |
| Avg. Daily Vol. (Mil) | 3.87 |
| Beta (3 year) | 0.76 |
| Share Related Items | |
| Mkt Cap (Mil) | 33,773.28 |
| Shares Out (Mil) | 852.00 |
| Float (Mil) | 0.00 |
| Dividend Information | |
| Yield % | 2.70 |
| Annual Dividend | 1.09 |
| Payout Ratio | 43.00 |
| Financial Strength | |
| Quick Ratio | 0.60 |
| Current Ratio | 1.20 |
| LT Debt/ Equity | 0.44 |
| Total Debt / Equity | 0.56 |
| Valuation Ratios | |
| Price Earnings | 19.70 |
| Price/Sales | 1.68 |
| Price/Book | 1.49 |
| Price/Cash Flow | 10.40 |
| Per Share Data | |
| Earnings | 2.01 |
| Sales | 23.61 |
| Book Value | 26.66 |
| Cash Flow | 3.83 |
| Business Summary | |
|---|---|
| Teva Pharmaceutical Industries Ltd develops, produces and markets generic, branded & OTC medicines. Some of its products are Copaxone, Azilect & Provigil. | |
| General Information | |
| 5 Basel Street
Petach Tikva, 49131 |
|
| www.tevapharm.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 45948 | |
| CEO: Jeremy M. Levin,D.Phil. | |
| Short Interest | |
| Current Month (Mil) | 10.85 |
| Previous Month (Mil) | 9.71 |
| Short Interest Ratio (Days) | 2.70 |
| Management Effectiveness | |
| Return on Equity | 7.40 |
| Return on Assets | 3.50 |
| Return on Investments | 5.20 |
| Profitability | |
| Gross Margin | 60.70 |
| EBIT Margin | 10.30 |
| Profit Margin | 8.40 |
Portfolios with TEVA
- Portfolio NameUser Type
- UserDonnie Portfolio 2 High Grade
- UserMain
- UserLong Term Stock Picks
- UserTRIG
- Userfun and games
- Userabangser Portfolio 1
- ContributorHighest-Yielding Drug Stocks
- Contributor8 Pharma Stocks to Watch
- Userdividend
- UserIncome stocks
Latest TEVA Headlines from TheStreet
- Teva Pharmaceutical Industries Ltd Stock Hold Recommendation Reiterated (TEVA) 04.18.13 | 10:04 am
- 5 Stocks Pulling The Drugs Industry Downward 04.12.13 | 01:04 pm
- Cramer's Top Stock Picks: BMY TEVA ROST BBBY 04.12.13 | 06:04 am
- Cramer's 'Mad Money' Recap: Bubble? What Bubble? 04.11.13 | 08:04 pm
- Teva Pharmaceutical Industries Ltd Stock Hold Recommendation Reiterated (TEVA) 04.08.13 | 10:04 am
- 3 Stocks Improving Performance Of The Health Care Sector 04.03.13 | 01:04 pm
- Teva Pharmaceutical Industries Ltd Stock Hold Recommendation Reiterated (TEVA) 03.28.13 | 10:03 am
- 4 Stocks Dragging The Drugs Industry Downward 03.27.13 | 01:03 pm
- Teva Pharmaceutical Industries Ltd Stock Hold Recommendation Reiterated (TEVA) 03.18.13 | 10:03 am
- Analysts' Actions: BTU HLS HPQ ODP TEVA 03.18.13 | 08:03 am
Press Releases for TEVA
- Teva Strengthens Respiratory Franchise With Acquisition Of MicroDose Therapeutx - Business Wire 06.17.13 | 09:06 am
- Teva Announces AZILECT® (Rasagiline Tablets) Data To Be Presented At The 2013 International Congress Of Parkinson’s Disease And Movement Disorders - Business Wire 06.14.13 | 08:06 am
- Alexza Announces Conference Call To Discuss Agreement With Teva To Market ADASUVE® In The U.S. - PR Newswire 05.08.13 | 08:05 am
- Teva And Alexza Announce Teva's License To Market ADASUVE® In The U.S. - PR Newswire 05.08.13 | 08:05 am
- OncoGenex Announces Plans For The Initiation Of The Rainier⿢ Clinical Trial Evaluating OGX-427 In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer - PR Newswire 05.01.13 | 06:05 am
- OncoGenex Announces That The Borealis-2â¿¢ Clinical Trial Of OGX-427 In Previously Treated Metastatic Bladder Cancer Is Now Open For Enrollment - PR Newswire 04.30.13 | 08:04 am
- More Than Half Of Nasal Allergy Sufferers Experience Sleep Issues, Yet Many Fail To Adequately Prepare In Advance Of Peak Allergy Seasons - PR Newswire 04.23.13 | 08:04 am
- Apolo Anton Ohno And Teva Respiratory Announce Finalists In National EIB All Starsâ¿¢ Contest - PR Newswire 04.16.13 | 08:04 am
- OncoGenex Announces Plans For The Initiation Of The Spruceâ¿¢ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Non-Squamous Non-Small Cell Lung Cancer - PR Newswire 04.11.13 | 08:04 am
- Early Versus Delayed Treatment With Laquinimod Demonstrated Significant Reduction In Risk Of Disability Progression – Results Of Three-Year ALLEGRO Study In Relapsing-Remitting Multiple Sclerosis - Business Wire 03.21.13 | 08:03 am
Partner Headlines for TEVA
- $2.15B Settlement for Pfizer's Protonix - Analyst Blog - Zacks 06.13.13 | 11:06 pm
- SGEN Starts Adcetris Phase I/II Study - Analyst Blog - Zacks 06.12.13 | 12:06 am
- FDA Accepts Teva sNDA - Analyst Blog - Zacks 06.01.13 | 12:06 am
- Obamacare Will Make this Pharmaceutical Company Skyrocket - NASDAQ 05.29.13 | 01:05 pm
- Teva Pharmaceutical Industries Limited Earnings Preview: Get Ahead of the Analysts - Wall St. Cheat Sheet 05.02.13 | 10:05 am
- Teva Pharmaceutical Industries Limited Earnings: Here’s Why the Stock is Up Now - Wall St. Cheat Sheet 05.02.13 | 09:05 am
- Analysts: SanDisk Will Beat Estimates and 4 New Opinions Investors Must Take Note Of - Wall St. Cheat Sheet 04.02.13 | 11:04 am
- 10 Sharp Healthcare Dogs Diagnose 7.4% To 62.1% Gains In March - Seeking Alpha 04.01.13 | 09:04 am
- FDA Approves NDA for Teva's Quartette Tablets to Prevent Pregnancy - Benzinga 03.29.13 | 11:03 am
- Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy - Seeking Alpha 03.28.13 | 09:03 am
